Medical/Pharmaceuticals
Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
SUZHOU, China and ROCKVILLE, Md., March 8, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the results from six preclinical studies of t...
2022-03-09 07:47
4206
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
SEATTLE, Wash. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- ProfoundBio announced that preclinical data from its pipeline of novel, proprietary antibody-drug conjugates (ADCs) and technology will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held Apr...
2022-03-09 06:58
5292
Omega Healthcare Acquires Reventics, a Physician Focused CDI and RCM Company
BOCA RATON, Fla., March 9, 2022 /PRNewswire/ -- Omega Healthcare, a leading healthcare management solutions partner supporting the broad healthcare ecosystem, today announced its acquisition of Reventics, aDenver, CO based company. Reventics is a clinical documentation improvement ("CDI") and re...
2022-03-09 06:38
2401
FIRST SURGERIES COMPLETED WITH PATIENT-SPECIFIC 3D PRINTED IMPLANTS PRODUCED AT THE LIMACORPORATE PROMADE POINT OF CARE CENTER AT HOSPITAL FOR SPECIAL SURGERY
UDINE, Italy, March 9, 2022 /PRNewswire/ -- LimaCorporate S.p.A., leading global orthopedics manufacturer, and Hospital for Special Surgery (HSS), consistently ranked number one in orthopedics globally by Newsweek and nationally byU.S. News & World Report in the U.S., today announced a new miles...
2022-03-09 06:16
2896
Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022
Gracell to present first-in-human data on GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy PALO ALTO, Calif. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage...
2022-03-09 05:30
2686
MediTrust Health invited three women who are fighting with diseases to share their views for March 8th Women's Day
SHANGHAI, March 8, 2022 /PRNewswire/ -- As the Women's Day is approaching, MediTrust Health invited three women who are fighting with diseases to share their views on one question - why do we need to live a sparkling life. We hope their answers will inspire and encourage those who are struggling ...
2022-03-08 18:22
2491
SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark
COPENHAGEN, Denmark, March 8, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory inCopenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and...
2022-03-08 15:31
2120
Nippon Express USA Acquires GDP Certification for CFS in Los Angeles and New York
TOKYO, March 8, 2022 /PRNewswire/ -- Nippon Express USA, Inc. (hereinafter "NX USA"), a group company of Nippon Express Holdings, Inc., has obtained Good Distribution Practice (GDP) certification for forwarding operations, inclusive of temporary storage, at temperature-controlled facilities in it...
2022-03-08 14:00
3692
Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC
HONG KONG, March 7, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the development of innovative antibody drugs, today announced that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has approved the IND...
2022-03-08 11:49
2473
WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies
PHILADELPHIA, March 7, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manu...
2022-03-08 08:00
2330
Bridge Biotherapeutics Enters into an Option-to-License Agreement with CellionBioMed to Develop BBT-301 for the Treatment of Multiple Fibrotic Diseases
* The company reinforces its strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF) * Through the option-to-license agreement, Bridge will develop a novel anti-fibrotic ion channel modulator, which is a preclinical candidate SEONGNAM, South Korea, March 7, 2022 /PR...
2022-03-08 08:00
2350
Suvoda Unveils New Brand to Reflect Expanded Focus in Complex Clinical Trial Management
Alongside brand refresh, leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey. PHILADELPHIA, March 8, 2022 /PRNewswire/ -- Suvoda LLC today launched a refreshed brand, to better reflect its leadership position as a g...
2022-03-08 08:00
2417
Singleron Acquires Proteona
NANJING/SUZHOU, China and COLOGNE, Germany and SINGAPORE, March 7, 2022 /PRNewswire/ -- Singleron Biotechnologies, a leading Chinese genomics company that develops groundbreaking single-cell multi-omics platform technologies and promotes their clinical translations, today announced the acquisitio...
2022-03-07 23:00
2743
Alterity Therapeutics to Present at the 34th Annual Roth Conference
MELBOURNE, Australia and SAN FRANCISCO, March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D.,...
2022-03-07 20:59
2771
Academic Stress and Emotional Well-Being in Students with Colour Vision Deficiency
KUALA LUMPUR, Malaysia, March 7, 2022 /PRNewswire/ -- Head of Optometry and Vision Science Programme from the Faculty of Health Sciences, Universiti Kebangsaan Malaysia (UKM), Prof DrSharanjeet Kaur Malkeet Singh found that students with congenital colour vision deficiency have emotional problems...
2022-03-07 10:00
4964
HCmed, Formosa Laboratories, and Formosa Pharmaceuticals Signed MoU to Form a Global CDMO for Inhalation Treatment Drugs
TAIPEI, March 7, 2022 /PRNewswire/ -- HCmed Innovations, Co., Ltd. (HCmed) announced that it has formed a strategic alliance with Formosa Laboratories, Inc. (TPEx: 4746) and Formosa Pharmaceuticals, Inc. (TPEx: 6838) to expand its business in the inhalation treatment field, providing contract dev...
2022-03-07 09:00
2890
AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer
GUANGZHOU, China, March 7, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. Marina Bibikova has come on board as Chief Scientific Officer (CSO). She will be responsible for cancer early detection technolo...
2022-03-07 09:00
3299
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients
SUZHOU, China, March 6, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its...
2022-03-07 08:18
4199
New Robotic Assisted Transperineal Needle-Guidance System for Prostate Biopsy and Cancer Ablations Received U.S FDA 510(k) Clearance
SINGAPORE, March 5, 2022 /PRNewswire/ -- Biobot Surgical is excited to announce U.S. FDA 510(k) clearance of the iSR'obot Mona Lisa 2.0. The new robotic assisted transperineal needle-guidance system allows urologists to plan and position a single needle or multiple needles during image-guided dia...
2022-03-05 20:00
4589
Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
* Phase 2 study of PVX108 to commence in United States and Australia * Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins University School of Medicine, joins Scientific Advisory Board MELBOURNE, Australia, March 4, 2022 /PRNewswire/ -- Aravax, a clinical stage biotechnology compa...
2022-03-04 21:00
3814
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21Toshiba Showcases Quantum-Safe Protection for Critical Infrastructure and Government Networks with SpeQtral and HPE
[Picked up by 261 media titles]
2026-10-06 09:00
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9663
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
9485
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8791
